Indian pharmaceutical B2B companies, including API manufacturers, contract development and manufacturing organisations (CDMOs), excipient and intermediate suppliers, are shortlisted by procurement and regulatory teams who search, and increasingly ask AI assistants, with precise criteria: the molecule, grade, regulatory filings, certifications and capacity. Being found depends on product pages that state those facts in text, a clear regulatory and quality section, consistent listings on industry platforms, and technical content written by qualified people. Marketing claims matter far less than verifiable detail.
How pharma buyers search
A typical question is specific: “Indian manufacturer of [API] with a US DMF and EU CEP, WHO-GMP certified, capacity in tonnes per year”. Assistants split it into the product, the filings, the certifications and the capacity, and look for pages that answer each part. A product list with names only answers none of them.
Product pages
| Element | Why it matters |
|---|---|
| Product name, CAS number and therapeutic category | Unambiguous identification |
| Grades and pharmacopoeia standards (IP, BP, USP, Ph. Eur.) | Buyers filter by the standard they need |
| Regulatory status: DMF, CEP, other filings, stated accurately | Often the first shortlisting criterion |
| Manufacturing site and its certifications or inspections | Quality and compliance evidence |
| Capacity and typical lead times | Answers supply questions |
| Documents available on request: CoA, SDS, technical packages | Shows readiness for qualification |
Only state filings and approvals you actually hold, with the correct status. Buyers verify them in regulators’ public databases.
Quality and regulatory section
- Sites, certifications and inspection history, stated factually
- Quality systems and the named people responsible
- Regulatory support offered to customers
- Environmental, health and safety practices
Rules on promotion
Promotion of medicines in India is governed by the Drugs and Cosmetics Act and related rules, the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, and the Uniform Code for Pharmaceutical Marketing Practices, updated in 2024. B2B pages for ingredients and services should stay factual and avoid therapeutic claims aimed at the public. Check with your regulatory team before publishing anything that describes clinical effects.
Listings and events
- Profiles on the B2B platforms and directories pharma buyers use, consistent with your site
- Export promotion council membership, such as Pharmexcil, where applicable
- Exhibitor pages at major industry events, which are often cited and linked
Technical content
- Articles by named chemists, regulatory and quality specialists
- Explanations of regulatory changes that affect buyers, dated and sourced
- Capabilities pages for technologies you offer, such as specific chemistry or scale-up
See SEO for manufacturers and exporters for the wider B2B approach, and international SEO for reaching overseas buyers.
Frequently asked questions
Should DMF numbers be published?
Many companies list DMF status and numbers, which are publicly searchable. Follow your regulatory team’s policy on what to disclose.
Is a product list enough?
No. Each important product needs its own page with the facts buyers filter on, or it will not match their questions.
Do AI assistants recommend pharma suppliers?
They answer supplier questions from web sources such as company sites, directories and filings. Clear, factual product pages make accurate mentions more likely.
Sources
- Drugs and Cosmetics Act, 1940, and Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954
- Department of Pharmaceuticals, Uniform Code for Pharmaceutical Marketing Practices, 2024
- US FDA and EDQM public databases for DMFs and CEPs